Scholarlink

Introduction <p>Sulopenem is a recently approved penem (in its oral formulation) by the Food and Drug Administration (FDA) for adult women with uncomplicated urinary tract infections that have limited or no other available therapeutic options. In this systematic review, we evaluated sulopenem resistance in Gram-negative and Gram-positive pathogens using the most recent published data.</p> Methods <p>Six resources, including Embase, Google Scholar, PubMed Central (PMC), PubMed, Scopus, and Web of Science, were used to identify relevant articles. The minimum inhibitory concentration (MIC) range, MIC<sub>50</sub>, MIC<sub>90</sub>, and resistance proportions were evaluated.</p> Results <p>After screening 477 articles, 11 studies were selected, comprising 9,768 isolates. Sulopenem demonstrated favorable activity against Enterobacterales and <i>Proteus mirabilis</i>, as well as good activity against methicillin-susceptible <i>Staphylococcus aureus</i> and <i>Klebsiella</i> species. Limited activity was observed against <i>Enterococcus</i> species, and no activity against methicillin-resistant <i>S. aureus</i> and <i>Pseudomonas aeruginosa</i>. Regarding <i>Escherichia coli</i>, the maximum MIC was &lt; 0.25&#xa0;mg/L in 5 of 9 (56%) studies with available data. For <i>Klebsiella pneumoniae</i> and <i>Proteus mirabilis</i>, the maximum MIC was &lt; 0.5&#xa0;mg/L in 5 of 8 (63%) studies with available data.</p> Discussion <p>Sulopenem showed activity against various pathogens, including both Gram-negative and Gram-positive bacteria. However, these observations were primarily based on MIC data for sulopenem against these pathogens. Further studies assessing the potential emergence of resistance to sulopenem using the recently published FDA susceptibility breakpoints would provide important epidemiological data of clinical relevance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A systematic review of data on the resistance of uropathogens to sulopenem

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Matthew E. Falagas,
  • Dimitrios S. Kontogiannis,
  • Dimitrios Ragias,
  • Charalampos Filippou

摘要

Introduction

Sulopenem is a recently approved penem (in its oral formulation) by the Food and Drug Administration (FDA) for adult women with uncomplicated urinary tract infections that have limited or no other available therapeutic options. In this systematic review, we evaluated sulopenem resistance in Gram-negative and Gram-positive pathogens using the most recent published data.

Methods

Six resources, including Embase, Google Scholar, PubMed Central (PMC), PubMed, Scopus, and Web of Science, were used to identify relevant articles. The minimum inhibitory concentration (MIC) range, MIC50, MIC90, and resistance proportions were evaluated.

Results

After screening 477 articles, 11 studies were selected, comprising 9,768 isolates. Sulopenem demonstrated favorable activity against Enterobacterales and Proteus mirabilis, as well as good activity against methicillin-susceptible Staphylococcus aureus and Klebsiella species. Limited activity was observed against Enterococcus species, and no activity against methicillin-resistant S. aureus and Pseudomonas aeruginosa. Regarding Escherichia coli, the maximum MIC was < 0.25 mg/L in 5 of 9 (56%) studies with available data. For Klebsiella pneumoniae and Proteus mirabilis, the maximum MIC was < 0.5 mg/L in 5 of 8 (63%) studies with available data.

Discussion

Sulopenem showed activity against various pathogens, including both Gram-negative and Gram-positive bacteria. However, these observations were primarily based on MIC data for sulopenem against these pathogens. Further studies assessing the potential emergence of resistance to sulopenem using the recently published FDA susceptibility breakpoints would provide important epidemiological data of clinical relevance.